Ignite Creation Date:
2024-05-06 @ 7:38 PM
Last Modification Date:
2024-10-26 @ 3:11 PM
Study NCT ID:
NCT06087263
Status:
RECRUITING
Last Update Posted:
2024-06-21
First Post:
2023-10-12
Brief Title:
Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets KIT Exon 17 18 or 14 Mutation and SDHB Deficient GIST in the Post-imatinib Second-line Setting
Sponsor:
Organization:
MD Anderson Cancer Center
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
30
Enrollment Type:
ESTIMATED
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE2 |
Observational Models:
Time Perspective List:
Who Masked List: